Tests tiprogrel against clopidogrel in people with recent ischemic stroke

Who can take part

• Age ≥ 40 years
• Acute Minor Ischaemic Stroke：AIS is defined as acute onset of neurological deficit attributed to focal brain ischaemia, NIHSS ≤5, and either of the following imaging characteristics:; Acute single infarction with ≥50% stenosis of a major intracranial or extracranial artery; Acute multiple infarctions attributed to large-artery atherosclerosis, including non-stenotic vulnerable plaques; TIA with high risk of stroke: ABCD2 score ≥ 6 at the time of randomization, and the following imaging characteristic:; a）TIA with ≥50% stenosis of a major intracranial or extracranial artery. 3）Can be treated with study drug within 24 hours of symptoms onset*(*Symptom onset is defined by the "last seen normal" principle) 4）A man or woman of childbearing potential does not have any plan to have a child from signing the informed consent to 3 months after the last dose 5）Written informed consent Exclusion Criteria
• Bleeding or other pathological brain disorders including malformation, tumor, abscess or other major non-ischemic brain disease on baseline head CT or MRI
• Isolated or pure sensory symptoms, isolated visual changes, or isolated dizziness/vertigo without evidence of acute infarction on baseline head CT or MRI
• Preceding mRS> 2
• Contraindication to anti-platelet therapy
• Clear indication for anticoagulation
• Two or more antiplatelet drugs have been used continuously for ≥3 days before enrollment
• Used heparin or oral anticoagulant drugs within 10 days before enrollment
• Undergone intravenous or arterial thrombolysis and mechanical thrombectomy within 24 hours before enrollment
• History of intracranial hemorrhage or amyloid angiopathy
• History of aneurysm
• Diagnosis or suspicious diagnosis of acute coronary syndrome
• History of asthma
• High-risk for bradyarrhythmia
• Anticipated requirement for long-term (>5 days) non-steroidal anti-inflammatory drugs or NSAIDs within the 8th day of randomization
• History of gastrointestinal bleeding within 3 months before enrollment or major surgery within 30 days
• Iatrogenic causes of minor stroke or TIA
• Planned or likely revascularization within the next 3 months, scheduled for surgery or interventional treatment requiring study drug cessation
• Severe non-cardiovascular comorbidity with life expectancy < 3 months
• Women of childbearing age who have not taken effective contraceptive measures and have a positive pregnancy test record, as well as women who are pregnant or breastfeeding
• Currently receiving an experimental drug or device
• Participation in another clinical study with an experimental product during the last 30 days
• Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders
• Hemoglobin <90g/L %
• Permanent hypertension
• Subjects who were judged by the investigator to be unsuitable for this clinical study